genetic medicines
AntiClastic™ Cyclic Oligonucleotide Platform
Discovery & Development Platform
Uniquely Shaping ASO and siRNA Innovation
The AntiClastic™ Cyclic Oligonucleotide platform turns your oligonucleotide ideas into differentiated, IP-secure drug candidates through true end-to-end collaboration. By reshaping ASOs, siRNAs, and sgRNAs into proprietary configurable cyclic architectures, we boost potency and in vivo stability while reducing off-target and immunostimulatory liabilities.
Our team integrates AI-guided sequence design, rapid lead discovery, systematic optimization, and development candidate selection to compress timelines and open access to next-generation RNA medicines for innovators worldwide.
Reshaping RNA Medicines
Reimagining Oligonucleotides’ Shape Enhances the Therapeutic Index
While oligonucleotide therapeutics are clinically validated, their widespread adoption has been hindered by high rates of clinical failure, as traditional linear constructs have failed to address off-target delivery, low potency, and unintended immunogenicity. These challenges stem from exposed molecular ends and a charged backbone that trigger unwanted interactions with proteins, immune receptors, and mismatched RNA sequences.
Cyclic Oligonucleotide Architectures
Cyclic architectures solve these foundational problems by re-engineering the molecule’s spatial conformation. In a transient cyclic design, the oligonucleotide forms a closed loop that provides two critical advantages:
Features
By hiding the reactive ends, the molecule evades unwanted binding to proteins, immune receptors, and partially matched RNAs.
The structure is engineered to remain “closed” until it encounters its perfectly matched RNA target, ensuring the molecule hybridizes only where intended.
The Genetic Medicine Difference
AntiClastics rely on the same clinically validated nucleotide chemistries as existing RNA medicines, keeping manufacturing compatible with established processes and best practices. The Alloy AntiClastic platform represents a step-change in functional performance, unlocking targets and mechanisms that legacy linear oligos, siRNA, and other nucleic acid modalities have struggled to address.
Developing Drug Candidates
The AntiClastic Cyclic Oligonucleotide Platform is a Collaborative Discovery Engine for Your Most Ambitious Targets
We don’t merely license technology; we deliver drug candidates. Our AntiClastic technology is the only solution accessible to discovery and development teams that supports ASO and siRNA drug candidate development, transforming your therapeutic concepts into IP-protected, clinic-ready assets by working with you to discover, design, build, test, and refine. From our AI/ML-enabled sequence Oligonucleotide Design Studio to in vivo testing, our team works hand in hand with you to develop promising RNA drug candidates.
Oligonucleotide Design Studio ML/Al-enabled, IP-protected constructs
Synthesis
Assay Development: Tailored to each program
High-throughput in vitro screening
in vivo testing
Innovation Infrastructure
Unlocking the Potential of RNA Therapeutics with AntiClastic Innovation
Resources
Join Us in Shaping the RNA Century
Whether you are a global pharma leader, biotech, academic team, or other industry stakeholder, partner with Alloy Genetic Medicines to deliver next-generation genetic medicines to patients who need them.
